Literature DB >> 21902530

Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance.

William C S Cho1.   

Abstract

MicroRNAs regulate target gene expression through translation repression or mRNA decay, and they are emerging as important modulators in cellular pathways. Previous studies have shown the occurrence of epigenetically modified miRNAs in colorectal cancer (CRC), identifying these miRNA methylation signatures may provide candidate markers for the detection of malignant colonocytes. Fecal-based tests are widely adopted as noninvasive methods for CRC diagnosis, thus several studies have attempted to use miRNAs from feces as CRC markers. This article evaluates a recently published study investigating the usefulness of epigenetically silenced miRNAs in fecal specimens, including miR-34b/c and miR-148a, as potential markers for CRC screening and prognosis.

Entities:  

Year:  2011        PMID: 21902530     DOI: 10.1586/erm.11.57

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  15 in total

Review 1.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Identification of Serum Exosomal hsa-circ-0004771 as a Novel Diagnostic Biomarker of Colorectal Cancer.

Authors:  Bei Pan; Jian Qin; Xiangxiang Liu; Bangshun He; Xuhong Wang; Yuqin Pan; Huiling Sun; Tao Xu; Mu Xu; Xiaoxiang Chen; Xueni Xu; Kaixuan Zeng; Li Sun; Shukui Wang
Journal:  Front Genet       Date:  2019-11-01       Impact factor: 4.599

3.  Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts.

Authors:  Hao Hu; Yi Zhang; Xian-Hua Cai; Ji-Feng Huang; Lin Cai
Journal:  Oncol Lett       Date:  2012-08-16       Impact factor: 2.967

4.  Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer.

Authors:  Feng Wang; Yanlei Ma; Huamin Wang; Huanlong Qin
Journal:  Oncol Lett       Date:  2017-01-11       Impact factor: 2.967

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

6.  Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo.

Authors:  Yantao Du; Zhaojun Liu; Liankun Gu; Jing Zhou; Bu-dong Zhu; Jiafu Ji; Dajun Deng
Journal:  BMC Cancer       Date:  2012-06-15       Impact factor: 4.430

7.  Impact of specific KRAS mutation in exon 2 on clinical outcome of chemotherapy- and radiotherapy-treated colorectal adenocarcinoma patients.

Authors:  Krzysztof Roszkowski; Bogdan Zurawski; Wojciech Jozwicki; Pawel Basta; Marzena Anna Lewandowska
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

8.  Multiple regression analysis of mRNA-miRNA associations in colorectal cancer pathway.

Authors:  Fengfeng Wang; S C Cesar Wong; Lawrence W C Chan; William C S Cho; S P Yip; Benjamin Y M Yung
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

Review 9.  Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection.

Authors:  Hicham Mansour
Journal:  Front Genet       Date:  2014-08-27       Impact factor: 4.599

10.  Development of a deregulating microRNA panel for the detection of early relapse in postoperative colorectal cancer patients.

Authors:  I-Ping Yang; Hsiang-Lin Tsai; Zhi-Feng Miao; Ching-Wen Huang; Chao-Hung Kuo; Jeng-Yih Wu; Wen-Ming Wang; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  J Transl Med       Date:  2016-04-29       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.